Business Wire

PATIENT-SAFETY-MOVEMENT

9.5.2018 16:32:11 CEST | Business Wire | Press release

Share
The Australian and New Zealand College of Anaesthetists Joins the Patient Safety Movement Foundation as a Committed Partner to Eliminate Preventable Harm in Hospitals

The Australian and New Zealand College of Anaesthetists (ANZCA) is partnering with the Patient Safety Movement Foundation (PSMF) in support of the mission to eliminate medical errors within hospitals - the 14 th leading cause of death worldwide. The announcement was made publicly at ANZCA’s Annual Scientific Meeting (ASM) in Sydney on May 8, 2018. Dr. Michael A. E. Ramsay, Anaesthetist, and Patient Safety Movement Foundation Board Member was present to sign the Commitment to Action Letter publicly alongside ANZCA President, Professor David A. Scott.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180509005874/en/

“We are thrilled to have the Australian and New Zealand College of Anaesthetists join us in our fight to eliminate preventable harm from hospitals. Through this partnership, we will reach the next generation of anaesthetists and recruit two important countries in our global effort to improve patient safety through the implementation of evidence-based processes,” explains Joe Kiani, Founder and Chairman of the Patient Safety Movement Foundation.

ANZCA runs one of Australasia’s largest specialist medical colleges and is the professional organisation representing nearly 6400 specialist anaesthetists and 1500 anaesthetists in training. ANZCA’s commitment represents the first by a major partner in Australia or New Zealand and joins 4,598 other committed hospitals and partners in 44 countries working towards the goal of eliminating preventable harm in hospitals.

“Patient harm and patient deaths occur in our hospitals daily, despite our best intentions. Many of these events are preventable if we apply existing knowledge, especially with the aid of new technologies. ANZCA welcomes this partnership which recognises our joint commitment to safety and quality in our specialty and improving patient safety,” said Professor Scott. “Initiatives such as this are so important for patients, hospitals and the specialty of anaesthesia.”

As a Committed Partner, ANZCA will work with the PSMF to improve patient outcomes with an acute focus on anesthesiology and perioperative care. Actions include:

    a.   Spreading the PSMF mission to ANZCA members;
 
b. Identifying Actionable Patient Safety Solutions (APSS) that align with ANZCA’s standards and/or policies and inviting members working in hospitals to implement APSS or similar processes with the aim of eliminating preventable patient deaths in hospitals;
 
c. Annually disseminating relevant APSS to ANZCA members;
 
d. Engaging with the PSMF at its annual meetings to develop and improve relevant APSS.
 

To learn more about the Patient Safety Movement Foundation, please visit www.patientsafetymovement.org .

About Patient Safety Movement Foundation: More than 200,000 people die every year in U.S. hospitals and 4.8 million worldwide in ways that could have been prevented. The Patient Safety Movement Foundation is a global non-profit which creates free tools for patients and hospitals. The Patient Safety Movement Foundation was established through the support of the Masimo Foundation for Ethics, Innovation, and Competition in Healthcare to reduce that number of preventable deaths to ZERO by 2020 (0X2020™). Improving patient safety will require a collaborative effort from all stakeholders, including patients, healthcare providers, medical technology companies, government, employers, and private payers. The Patient Safety Movement Foundation works with all stakeholders to address the problems with actionable solutions for patient safety. The Foundation also convenes the World Patient Safety, Science & Technology Summit. The Summit brings together some of the world’s best minds for thought-provoking discussions and new ideas to challenge the status quo. By presenting specific, high-impact solutions to meet patient safety challenges, called Actionable Patient Safety Solutions, encouraging medical technology companies to share the data their products are purchased for, and asking hospitals to make commitments to implement Actionable Patient Safety Solutions, the Patient Safety Movement Foundation is working toward ZERO preventable deaths by 2020. Visit patientsafetymovement.org.

About ANZCA: The Australian and New Zealand College of Anaesthetists (ANZCA) is the professional organisation for about 6400 specialist anaesthetists (Fellows) and 1500 anaesthetists in training (trainees). One of Australia's largest specialist medical colleges, ANZCA, along with its Faculty of Pain Medicine, is responsible for the training, examination and specialist accreditation of anaesthetists and pain medicine specialists and the standards of clinical practice in Australia and New Zealand. The College also plays a significant role in the advancement of anaesthesia in southeast Asia and South Pacific island countries.

Contact:

Patient Safety Movement Foundation
Tanya Lyon, Public Relations Manager
(949) 351-2858
tanya.lyon@patientsafetymovement.org
or
Australian & New Zealand College of Anaesthetists
Carolyn Jones, Media Manager
+61 3 8517 5303
cjones@anzca.edu.au

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Kubota Vision Inc. Signs Supply and Licensing Agreement with Laboratoires KÔL for Stargardt Disease Treatment Candidate Under Compassionate Use4.5.2026 17:16:00 CEST | Press release

Kubota Vision Inc. (“Kubota Vision”), a wholly-owned subsidiary of Kubota Pharmaceutical Holdings Co., Ltd. (Minato-ku, Tokyo, Japan) announced signing of a Supply and Licensing Agreement with Laboratoires KÔL (Clermont-Ferrand, France) for the provision of a Stargardt disease (STGD1) treatment candidate under compassionate use authorization. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260414590785/en/ The purpose of this Agreement is for Kubota Vision and KÔL to collaborate on providing “Emixustat” for treatment of Stargardt Disease (STGD1) through compassionate use authorization in France. Kubota Vision will exclusively manufacture and supply Emixustat final products to KÔL and KÔL will have exclusive rights to distribute Emixustat in France under compassionate use access. Ryo Kubota, Chairman, President, and CEO of Kubota Pharmaceutical Holdings, stated, “We are extremely pleased to enter into this Agreement with Labor

Incentive Market Set to Surpass $80B by 2030s — IMA Launches Tools to Help the Industry Keep Pace4.5.2026 16:28:00 CEST | Press release

With combined business spend on loyalty, employee recognition, and channel incentives projected to exceed $80 billion by the 2030s, the incentive industry is entering a period of rapid scale and strategic pressure. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260422729016/en/ In response, the Incentive Marketing Association (IMA) launched a new suite of resources designed to help incentive professionals navigate an environment that’s becoming more specialized, fragmented, and central to business performance. “It’s not just more money coming in—it’s more complexity,” said Vince Chiofolo, President of the Incentive & Engagement Solution Providers (IESP). “Buyers are demanding programs that evolve fast, integrate deeply, and feel personal at scale. These new tools were built for that.” IMA’s Suite of Tools Includes: New Industry Report — Inside the Incentive Buyer’s Mind Drawn from insights of 50+ program owners, the report f

Tigo Energy Breaks Global Growth Benchmark; Boosts U.S. Energy Feature in Predict+4.5.2026 15:00:00 CEST | Press release

Advanced energy prediction platform adds real-time energy pricing for North American Independent System Operator (ISO) customers, accelerates meters-connected growth. Tigo Energy, Inc. (NASDAQ: TYGO) (“Tigo” or “Company”), a leading provider of intelligent solar and energy solutions, today announced that the Predict+ platform now offers integrated real-time spot market pricing for ISO customers in the United States. Predict+ provides utilities with deep insights into grid demand, renewable generation, and energy market dynamics, enhancing the precision, scalability, and robustness of energy forecasting to up to 97.5% accuracy through machine learning and artificial intelligence. For energy providers, Predict+ helps streamline operations, reduce volatility, and maximize performance. Predict+ empowers utility operators to adapt to real-world demand challenges when balancing renewable and baseload generation sources, particularly during extreme weather events and market disruptions. On th

Airship Announces 2026 Elevate Customer Experience Award Winners4.5.2026 15:00:00 CEST | Press release

Southwest Airlines, The Economist, and OneFootball among brands recognized at Elevate’26 Customer Experience Summit for setting the standard in mobile-first and AI-centered customer experiences Airship, the mobile-first customer experience company, today announced the winners of the 2026 Elevate Customer Experience Awards. Global brand leaders from The Economist, Southwest Airlines, and OneFootball were among those honored at the Elevate’26 Customer Experience Summit. The Elevate Awards spotlight global companies that have developed exceptional mobile-first customer experiences for their customers, created innovative campaigns, leveraged AI agents to reach new levels of productivity, and achieved real business results. "Evolving mobile-first consumer behaviors and unprecedented advancements in AI are driving a seismic shift that is reshaping how brands interact with their customers," said Brett Caine, CEO, Airship. "The 2026 Elevate Award winners aren’t just adapting, they’re leading t

Alnylam to Present New Analyses at Heart Failure 2026 Underscoring Consistent Clinical Profile of Vutrisiran in ATTR-CM4.5.2026 14:30:00 CEST | Press release

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced it will present new data analyses for vutrisiran in patients with the cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM) at Heart Failure 2026, a scientific congress of the European Society of Cardiology, taking place May 9-12, 2026, in Barcelona, Spain. ATTR-CM is a heterogeneous and rapidly progressive disease, and patients often present with complex clinical profiles. At Heart Failure 2026, Alnylam will present multiple new analyses from the Phase 3 HELIOS-B study of vutrisiran, which continue to support its use as a first-line treatment for patients with ATTR-CM, and further characterize its clinical profile across patients with a high disease burden, and in the context of concomitant therapies. Vutrisiran is the first and only transthyretin (TTR) silencer for ATTR-CM that delivers rapid knockdown of TTR at the source. Additional analyses being pr

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye